他达拉非(Tadalafil) - 药物靶点：PDE5A_在研适应症：前列腺增生症，家族性肺动脉高压，肺动脉高压_专利_临床

概要

基本信息

简介他达拉非（Tadalafil）是一种磷酸二酯酶5型（PDE5）抑制剂药物，商标名为“Cialis”，与西地那非（Viagra）和伐地那非（Levitra）同属一类药物。他达拉非于2003年11月21日首次获得FDA批准用于治疗勃起功能障碍（ED）。它由ICOS Corporation制药公司开发，由Eli Lilly and Company销售。除了获得勃起功能障碍的批准外，他达拉非还获得了FDA批准用于治疗良性前列腺增生症（BPH）和肺动脉高压（PAH）。

药物类型

小分子化药

别名

Tadalafil (JAN/USP/INN)、Tadalafil Film Coated Tablets(Akums)、Tadalafil Technosphere(MannKind)

+ [31]

靶点

PDE5A

作用方式

抑制剂

作用机制

PDE5A抑制剂(磷酸二酯酶-5A抑制剂)

治疗领域

呼吸系统疾病泌尿生殖系统疾病其他疾病

在研适应症

前列腺增生症家族性肺动脉高压肺动脉高压+ [2]

非在研适应症

镰状细胞血症CREST综合征糖尿病+ [16]

原研机构

Eli Lilly & Co.

ICOS Corp.

在研机构

Eli Lilly Nederland BV

Eli Lilly & Co.

Viatris, Inc.

+ [5]

非在研机构

B BETTER LLC

MannKind Corp.

Mylan NV

+ [5]

权益机构

齐鲁制药有限公司IntelGenx Corp.

A.Menarini Industrie Farmaceutiche Riunite Srl

+ [10]

最高研发阶段批准上市

首次获批日期

澳大利亚 (2002-10-23),

勃起功能障碍

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C22H19N3O4

InChIKeyWOXKDUGGOYFFRN-IIBYNOLFSA-N

CAS号171596-29-5

关联

523

项与他达拉非相关的临床试验

CTIS2025-521819-39-00

/ Not yet recruiting临床2期IIT

Prospective, Open-Label, Single-Center Pilot Study on the Efficacy of Daily Tadalafil in Early-Stage Parkinson’s Disease

开始日期2026-03-01

申办/合作机构-

NCT07466030

/ Not yet recruiting临床1期IIT

Impact of Daily Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate :A Randomized , Single Blinded ,Controlled Trial"

The aim of this study is to evaluate the impact of daily tadalafil 5 mg on storage lower urinary tract symptoms (LUTS) during the early postoperative period following Anatomical endoscopic enucleation of prostate in a randomized controlled clinical trial.

开始日期2026-03-01

申办/合作机构

Assiut University

CTR20260148

/ CompletedN/A

武汉东信医药科技有限责任公司研制的他达拉非片与原研参比制剂在中国健康男性受试者中进行的单中心、随机、开放、两制剂、餐后、单次给药、两周期、双交叉设计的生物等效性研究

以武汉东信医药科技有限责任公司研制的他达拉非片（规格：20 mg）为受试制剂，持证商为A. Menarini GmbH、生产商为Menarini-von Heyden Gmbh（MvH）的他达拉非片（商品名：希爱力®/Cialis®，规格：20 mg）为参比制剂，考察两制剂在餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性。

开始日期2026-01-24

申办/合作机构

武汉东信医药科技有限责任公司

100 项与他达拉非相关的临床结果

登录后查看更多信息

100 项与他达拉非相关的转化医学

登录后查看更多信息

100 项与他达拉非相关的专利（医药）

登录后查看更多信息

3,766

项与他达拉非相关的文献（医药）

2026-12-31·RENAL FAILURE

Landscape of diabetic kidney disease drug clinical trials in China (2013–2023): global implications for innovation and policy

Review

作者: Xiao, Zheng ; Tan, Huifang ; Chen, Yinyin ; Zhu, Jiayu ; Li, Guoli ; Yang, Yiya

With the increasing prevalence of diabetes, the incidence rate of diabetic kidney disease (DKD) has risen yearly in China. While traditional therapies like renin-angiotensin system blockers remain foundational, the treatment paradigm is rapidly evolving with the emergence of novel agents, including SGLT2 inhibitors, mineralocorticoid antagonists, endothelin receptor antagonists, and GLP-1 receptor agonists. This study aims to provide an overview of the changing landscape of drug clinical trials on DKD in mainland China from 2013 to 2023. Detailed information of drug trials for DKD registered on the National Medical Products Administration Registration and Information Disclosure Platform for Drug Clinical Studies was collected. A total of 50 trials for DKD were included. Bioequivalence trials accounted for the most significant proportion (48%), followed by phase II (22%), phase I (20%), and phase III (10%). Chemical drugs accounted for the largest proportion (92%), followed by traditional Chinese medicine/natural medicine (8%). There were 18 different drugs involved in the 50 trials with Irbesartan (n = 24, 48%) ranked first in the number of trials. The parallel-group design was primarily used (48%), followed by crossover design (46%). Randomization was used by almost all trials (92%). Of all trials, 44 (88%) were launched domestically, whereas only 6 (12%) were international multi-center trials. Drug trials showed an uneven geographical distribution. Despite the progress in DKD drug clinical trials in mainland China during recent years, innovative drug research and development still has a long way to go. These findings provide an evidence base for optimizing global-regional alignment in DKD innovation policy.

2026-05-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Glycyl-l-histidyl-l-lysine as a novel co-former in co-amorphous systems: Enhanced aqueous solubility and physical stability

Article

作者: Liang, Guang ; Yuan, Yinyin ; Zou, Zhiren ; Huang, Qiang ; Wu, Wencheng ; Cheng, Dian ; Gao, Ruyu ; Wu, Wenqi ; Zhou, Lin ; Huang, Yuye ; Chun, ChangJu

Co-amorphous systems have emerged as a promising strategy to enhance the aqueous solubility of poorly water-soluble drugs. Although amino acids have been widely studied as co-formers, some amino acid-based co-amorphous systems exhibit limited dissolution improvement and inadequate physical stability. In this study, glycyl-l-histidyl-l-lysine (GHK) was selected as a co-former due to its biocompatibility and multiple functional groups, which were expected to enhance the dissolution and the physical stability of pure amorphous drugs. Basic mebendazole, neutral tadalafil and acidic indomethacin were selected as the model drugs. Glycine, histidine and lysine were used as co-formers for comparison. All drug-co-former combinations were prepared by ball milling at a 1:1 molar ratio. GHK achieved complete amorphization with all three model drugs within 15 min of milling, whereas most amino acid-based mixtures remained partially crystalline even after 60 min of milling. The formation of homogeneous amorphous forms was confirmed by differential scanning calorimetry, indicated by a single glass transition temperature in the drug-GHK system. The drug-GHK systems exhibited significantly enhanced dissolution performance, including faster dissolution rates, higher drug concentration and sustained supersaturation (up to 1440 min) compared to both the pure crystalline and amorphous drugs. Furthermore, physical stability studies confirmed that GHK-based systems maintained amorphous forms for at least 6 months, outperforming both amino acid-based counterparts and pure amorphous drugs. Notably, salt formation and hydrogen bonding were associated with the observed improvements in dissolution performance and physical stability. In conclusion, GHK represents a promising co-former, expanding the design space for co-amorphous systems.

2026-04-01·BJU INTERNATIONAL

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial

Article

作者: Ha, U‐Syn ; Han, Jun Hyun ; Kim, Won Tae ; Lee, Seung Wook ; Jeong, In Gab ; Oh, Cheol Young ; Lee, Gyeongseop ; Song, Sang Hoon ; Noh, Joon Hwa ; Min, Gyeong Eun ; Kim, Jae Heon ; Chung, Byung Ha ; Moon, Kyung Hyun ; Han, Deok Hyun ; Park, Hyun Jun ; Lee, Ji Youl ; Lee, Sangchul ; Lee, Seung Hwan ; Lee, Jun Ho ; Kim, Choung‐Soo ; Kang, Taek Won

Objectives:

To evaluate the efficacy and safety of a fixed‐dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH).

Patients and Methods:

This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom Score (IPSS) and randomised (1:1:1) to receive FDC dutasteride 0.5 mg/tadalafil 5 mg (FDC 0.5/5 mg), dutasteride 0.5 mg, or tadalafil 5 mg for 48 weeks. The primary endpoint was the change in total IPSS from baseline to Week 48. Efficacy and safety were assessed at 4, 12, 24, 36, and 48 weeks.

Results:

In total, 619 patients were analysed for efficacy. The least squares (LS) mean (standard error [ se] ) change in total IPSS at 48 weeks from baseline was −9.49 (0.37) for the FDC 0.5/5 mg group vs –4.40 (0.37) for dutasteride 0.5 mg group (LS mean difference [LSMD] –5.09, 95% confidence interval [CI] −6.13 to −4.50; P < 0.001), and −9.53 (0.36) for the FDC 0.5/5 mg group vs –4.24 (0.37) for tadalafil 5 mg group (LSMD –5.29, 95% CI −6.30 to −4.27; P < 0.001). The FDC 0.5/5 mg group demonstrated the most pronounced improvement in quality of life. Although the maximum urinary flow rate and post‐void residual volume improved in all groups, differences were not statistically significant. In the comparison between the FDC 0.5/5 mg and dutasteride 0.5 mg groups, the LSMD (95% CI) of change from baseline to Week 48 in the international index of erectile function ‐ erectile function (IIEF ‐ EF) total score was 4.03 (2.35 to –5.71) ( P < 0.05). Among the 655 patients analysed for safety, treatment‐emergent adverse events occurred in 32.88% (FDC 0.5/5 mg) vs 21.20% (dutasteride 0.5 mg) and 26.48% (tadalafil 5 mg), with few serious adverse events observed.

Conclusions:

The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

909

项与他达拉非相关的新闻（医药）

2026-04-02

·动脉网

【里程碑】中美双报获批，全球首创GRK2分子胶有望逆转肺动脉高压血管重构

近日，南京寰柏生物科技有限公司（以下简称“寰柏生物”）宣布，其全球首创肺动脉高压新药AF02（口服分子胶），同步获FDA与CDE的新药临床试验（IND）批准。 01 全球首创靶向GRK2分子胶，从缓解症状到逆转重构从发病机制来看，肺动脉高压（pulmonary hypertension，PH）是由多种异源性疾病和不同发病机制所致的肺血管结构或功能改变，引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征，继而发展成右心衰竭甚至死亡。寰柏生物官网显示，肺动脉高压预后差，中位生存期仅2.8年；1、3和5年生存率分别为68%、48%和34%。因致死率极高，肺动脉高压也被称为心血管“癌症”。肺动脉高压发病机制，图片来源科研综述从分子机制层面看，肺动脉高压的发生主要涉及三大信号通路的紊乱。分别是一氧化氮（NO）通路功能受损、前列环素（PGI2）通路受损、内皮素-1（ET-1）信号通路过度激活。基于三大信号通路，此前的肺动脉高压靶向药物主要分为三类，分别是磷酸二酯酶抑制剂与可溶性鸟苷酸环化酶激动剂（一氧化氮通路，例如西地那非、他达拉非、利奥西呱）；前列环素及其类似物、前列环素IP受体激动剂（前列环素通路，例如吸入伊洛前列素、皮下和静脉注射曲前列尼尔、司来帕格）；内皮素受体拮抗剂（内皮素通路，例如波生坦、安立生坦、马昔腾坦）。三大信号通路，图片来源科研综述但肺动脉高压的核心病理改变为“血管重塑”（Vascular Remodeling），是指肺动脉小血管的结构发生了永久性的、恶性的改变，从而造成血流通过肺血管时的阻力增大，导致缺氧和右心功能衰竭。现有靶向药如波生坦、西地那非、利奥西呱等，只能促进肺血管扩张，缓解患者症状，但对于已经发生的“血管重塑”逆转能力有限，不能从源头上抑制疾病进展，即治标不治本。 AF02的核心优势在于，这是一款以血管重构逆转为核心机制的肺动脉高压创新药物。其临床前研究数据显示，AF02拥有超行业常规标准的安全边际，构建了极宽的“治疗安全带”，有望推动肺动脉高压的治疗目标从“延缓死亡”迈向“趋于正常”。由于AF02目前还处于临床早期研究阶段，暂未披露更多关于靶点、机制、有效性及安全性的数据。不过，我们可以从其合作伙伴分迪药业的公开信息中得出部分信息。分迪药业报道，AF02是一款靶向GRK2的口服分子胶药物，其开发借助了分迪药业自主研发的 Prodedrug®分子胶合理设计平台。从靶点机制来看，有研究表明，在肺动脉高压患者及动物模型中，GRK2表达水平上调，通过调控YAP信号通路，可促进肺动脉平滑肌细胞（PASMCs）的增殖、迁移和血管重构。因此，基于该机制开发口服分子胶，可抑制GRK2活性或表达，从而阻断YAP信号通路，减少PASMCs异常增殖和血管重构，而非仅缓解症状，有望从根源上遏制疾病进展。 02 首款逆转血管重构的药物已获批上市事实上，在逆转肺动脉高压血管重构方面，已有默沙东的欣瑞来（注射用索特西普，Sotatercept）获批上市。作为全球首个针对肺动脉高压核心病理机制——血管重构的激活素信号传导抑制剂，Sotatercept机制独特，其是一种首创激活素受体型IIA（ActRIIA）融合蛋白，通过结合激活素配体TGF-β亚家族成员，来阻断其与ActRIIA受体的结合，从而抑制ActRIIA-Smad2/3信号通路，改善促增殖和抗增殖信号之间的平衡来调节肺动脉高压背后的血管细胞增殖，达到抑制肺血管重构的效果。 Sotatercept机制，图源默沙东官网该药最初由Acceleron开发，原本用于治疗化疗所致的贫血和骨质流失。研究人员偶然发现它在肺动脉平滑肌细胞的促增殖信号方面有重要作用，于是在2017年转向肺动脉高压研究。2021年9月，默沙东以115亿美元收购Acceleron，从而获得Sotatercept。2024年3月，Sotatercept获FDA批准上市，适应症为成人肺动脉高压（PAH，WHO 1组肺高血压）。随后，该药又在2024年8月获EMA批准上市，2025年6、7月份在日本、韩国陆续获批上市，今年1月获NMPA批准上市。 Sotatercept获批基于其全球关键Ⅲ期临床试验STELLAR研究数据。研究结果显示，与安慰剂联合背景治疗相比，Sotatercept治疗24周后，使患者的6分钟步行距离较基线显著增加41米，这一改善具有高度的临床与统计学意义，直接证实其提升患者运动耐量的核心价值。重要的是，该药物在影响疾病进程的“硬终点”上展现出强大优势，能将患者发生死亡或肺动脉高压相关临床恶化事件的风险显著降低84%。在安全性方面，其耐受性良好，最常见的不良反应包括红细胞增多、血小板减少、毛细血管扩张等，大多可控。 DelveInsight报告显示，在肺动脉高压领域，全球约有超55家公司正在积极推进超55个治疗候选物。Keros Therapeutics、Gossamer Bio、辉瑞、宜明昂科、来凯医药等国内外药企，均有相关布局。但目前仅Sotatercept是唯一获批上市且明确以逆转肺血管重构为目标的药物，其他管线仍处于研发阶段，因此逆转肺血管重构的竞争格局并不算拥挤。 *封面图片来源：123rf 如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。动脉网，未来医疗服务平台

2026-03-31

·EINPresswire

Boner Bears Honey may be harmful due to hidden drug ingredients

[3-30-2026] The Food and Drug Administration is advising consumers not to purchase or use Boner Bears Honey, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores. This product was identified during an FDA inspection of Pure Vitamins and Natural Supplements LLC, in Tampa. Boner Bears Honey has been recalled by one of its distributors – Pure Vitamins and Natural Supplements. Visit the company’s press release for more information. FDA laboratory analysis confirmed that Boner Bears Honey contains sildenafil and tadalafil not listed on the product label. Sildenafil and tadalafil are the active ingredients in the FDA-approved prescription drugs Viagra and Cialis, respectively, used to treat erectile dysfunction. FDA approval of Viagra and Cialis is restricted to use under the supervision of a licensed health care professional. These undeclared ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. People with diabetes, high blood pressure, high cholesterol or heart disease often take nitrates. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 03/30/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2026-03-31

·drugs

Sex Enhancement Chocolates Recalled Over Hidden Drug Ingredients

TUESDAY, March 31, 2026 — Two chocolate products marketed for sexual enhancement are being recalled because they were found to contain hidden prescription drug ingredients. The recall involves "Gold Lion Aphrodisiac Chocolate" and "ilum Sex Chocolate," sold by the company Gear Isle , according to the U.S. Food and Drug Administration (FDA). Officials said the products contain sildenafil and tadalafil , but these ingredients were not listed on the label. Hidden drug ingredients can be dangerous, especially for folks taking certain medications. Anyone who takes nitrates for a heart condition, such as nitroglycerin, is at particular risk, the FDA’s announcement said. Combining nitrates with sildenafil or tadalafil can cause a sudden and potentially life-threatening drop in blood pressure. Health officials warn that this risk is especially important for adult men, who are more likely to use both these products and heart medications. So far, no illnesses have been reported. The recalled items include: Gold Lion Aphrodisiac Chocolate UPC: 795847916279 UPC: 795847916279 Expires June 2027 Expires June 2027 ilum Sex Chocolate UPC: 1002448578911 UPC: 1002448578911 Expires Dec. 25, 2027 Expires Dec. 25, 2027 Both products were sold online across the United States and labeled as dietary supplements. Gear Isle says customers should stop using the products right away and return them for a refund. Anyone who has used the products and feels sick should contact a doctor immediately. Sources U.S. Food and Drug Administration, news release, March 26, 2026

100 项与他达拉非相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02008	他达拉非	G04BE08	DB00820

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
前列腺增生症	美国	Eli Lilly & Co.	2011-10-06
家族性肺动脉高压	欧盟	Eli Lilly Nederland BV	2008-10-01
家族性肺动脉高压	冰岛	Eli Lilly Nederland BV	2008-10-01
家族性肺动脉高压	列支敦士登	Eli Lilly Nederland BV	2008-10-01
家族性肺动脉高压	挪威	Eli Lilly Nederland BV	2008-10-01
肺动脉高压	欧盟	Eli Lilly Nederland BV	2008-10-01
肺动脉高压	冰岛	Eli Lilly Nederland BV	2008-10-01
肺动脉高压	列支敦士登	Eli Lilly Nederland BV	2008-10-01
肺动脉高压	挪威	Eli Lilly Nederland BV	2008-10-01
勃起功能障碍	澳大利亚	Eli Lilly Australia Pty Ltd.	2002-10-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	临床3期	美国	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	日本	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	阿根廷	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	比利时	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	法国	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	德国	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	意大利	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	荷兰	Eli Lilly & Co.	2013-09-01
杜氏肌营养不良症	临床3期	俄罗斯	Eli Lilly & Co.	2013-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03993353 (CTgov)	临床2期	转移性头颈部鳞状细胞癌 \| 晚期头颈癌 \| 食管癌 ... 更多	7	Pembrolizumab+Tadalafil	蓋遞範蓋衊遞糧觸積艱 = 鹽範簾範艱鬱蓋簾構觸願衊積淵蓋遞淵獵艱鹽 (齋鬱願範夢構艱膚願構, 鬱繭觸廠網繭糧膚顧構 ~ 衊積製夢夢遞觸襯觸窪) 更多	-	2026-02-12
NCT05173896 (ETLAS-2, Pubmed \| Stroke)	临床2期	脑小血管疾病	76	Tadalafil 20 mg	壓積窪顧淵艱願鹹積蓋(衊構鹽鑰壓願鑰淵築構): OR = 5.49 (95.0% CI, 1.81 ~ 18.07), P-Value = 0.001 更多	不佳	2025-10-01
				Placebo
NCT01865084 (Pubmed \| BMC Cardiovasc Disord)	临床3期	杜氏肌营养不良症	331	Tadalafil 0.6 mg/kg/day	願願積顧襯夢齋憲製膚(衊淵膚艱蓋顧製糧廠膚) = 遞齋製齋積鑰遞鏇顧艱積簾膚衊鑰觸憲餘糧壓 (齋餘遞憲鏇繭簾觸糧獵 )	积极	2025-04-11
NCT05173896 (ETLAS-2, Pubmed \| Cereb Circ Cogn Behav)	临床2期	脑小血管疾病	60	Tadalafil 20 mg	蓋廠淵蓋齋壓積願構鏇(網築壓鹹鑰齋觸壓廠淵) = 簾鏇製窪網範廠糧鹹膚製淵襯膚憲糧鹽糧構觸 (積築醖淵鑰衊觸齋夢製, 13.8)	不佳	2025-01-01
				Placebo	-
FDA_CDER 人工标引	N/A	前列腺增生症 \| 勃起功能障碍	606	Placebo	製獵醖夢簾膚願膚衊觸(鑰製餘鏇顧廠顧壓窪夢) = 積觸願膚衊衊遞繭餘積範壓衊觸鬱遞製範壓築 (襯願鑰鏇襯繭餘窪鑰網 ) 更多	积极	2024-06-28
				Tadalafil 5 mg	製獵醖夢簾膚願膚衊觸(鑰製餘鏇顧廠顧壓窪夢) = 獵憲獵鏇遞觸壓夢構遞範壓衊觸鬱遞製範壓築 (襯願鑰鏇襯繭餘窪鑰網 ) 更多
FDA_CDER 人工标引	N/A	勃起功能障碍	402	Placebo (Study A + US Trials)	構餘製蓋願積醖範觸構(齋鏇廠夢廠衊餘壓鹹餘) = 糧選鑰鹹製窪蓋窪鏇鹹壓構淵鹽廠艱壓艱範淵 (選選鏇鬱衊築餘窪獵齋 ) 更多	积极	2024-06-28
				TadalafilTadalafil 20 mg (Study A + US Trials)	構餘製蓋願積醖範觸構(齋鏇廠夢廠衊餘壓鹹餘) = 選淵蓋範觸顧觸淵淵壓壓構淵鹽廠艱壓艱範淵 (選選鏇鬱衊築餘窪獵齋 ) 更多
FDA_CDER 人工标引	N/A	前列腺增生症	-	Placebo (Study J)	壓顧簾獵築艱遞鏇艱觸(遞艱憲襯淵鬱鹽選選壓) = 鏇顧範顧繭蓋艱齋鹽鹽範膚築淵鬱鏇淵遞網艱 (鏇艱壓襯構鹹獵願窪鹹 )	积极	2024-06-28
				Tadalafil 5 mg (Study J)	壓顧簾獵築艱遞鏇艱觸(遞艱憲襯淵鬱鹽選選壓) = 選網衊願繭襯鏇觸廠製範膚築淵鬱鏇淵遞網艱 (鏇艱壓襯構鹹獵願窪鹹 )
FDA_CDER 人工标引	N/A	前列腺增生症	696	Placebo and finasteride 5 mg	廠顧鹹壓構鬱願鏇齋鹽(齋構廠窪選淵蓋夢壓鹹) = 築鏇鹽顧艱淵壓遞鹽廠鑰繭繭鹽選窪簾願鑰網 (觸廠簾淵艱遞窪蓋蓋鹹 ) 更多	积极	2024-06-28
				Tadalafil 5 mg and finasteride 5 mg	廠顧鹹壓構鬱願鏇齋鹽(齋構廠窪選淵蓋夢壓鹹) = 積網觸艱鹹憲繭醖繭膚鑰繭繭鹽選窪簾願鑰網 (觸廠簾淵艱遞窪蓋蓋鹹 ) 更多
FDA_CDER 人工标引	N/A	勃起功能障碍	1,112	Placebo (Outside the US)	廠衊鬱顧蓋衊壓壓鹹艱(鏇衊觸遞網糧積憲構糧) = 衊艱餘廠簾膚顧夢膚鑰糧鹹糧窪繭膚構鹹齋鬱 (範選顧襯簾膚鏇鹽夢築, 0.7) 更多	积极	2024-06-28
				TadalafilTadalafil 5 mg (Outside the US)	廠衊鬱顧蓋衊壓壓鹹艱(鏇衊觸遞網糧積憲構糧) = 鬱網憲衊鬱鑰蓋壓範構糧鹹糧窪繭膚構鹹齋鬱 (範選顧襯簾膚鏇鹽夢築, 4.0) 更多
NCT05487755 (Pubmed) 人工标引	临床3期	糖尿病肾病辅助	90	Tadalafil 20 mg	衊淵製衊醖糧糧築憲鏇(蓋醖遞鹽艱選鏇範餘鹽) = 積網廠簾壓窪醖觸淵鏇構壓衊顧願觸憲憲壓願 (衊願艱壓廠壓壓鑰淵顧 )	积极	2024-06-24
				Pentoxifylline 400 mg	衊淵製衊醖糧糧築憲鏇(蓋醖遞鹽艱選鏇範餘鹽) = 簾選襯網蓋願簾願鏇構構壓衊顧願觸憲憲壓願 (衊願艱壓廠壓壓鑰淵顧 )